Pharming Group (NASDAQ:PHAR) Shares Gap Up – Should You Buy?

Pharming Group (NASDAQ:PHAR)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $9.09, but opened at $9.50. Pharming Group shares last traded at $9.64, with a volume of 3,700 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th. Finally, Oppenheimer dropped their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th.

Pharming Group Stock Up 4.5 %

The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The business’s 50 day moving average is $8.98 and its 200-day moving average is $8.42. The stock has a market cap of $644.05 million, a price-to-earnings ratio of -36.52 and a beta of -0.08.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.